CORT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CORT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Corcept Therapeutics's Forward PE Ratio for today is 149.27.
Corcept Therapeutics's PE Ratio without NRI for today is 24.19.
Corcept Therapeutics's PE Ratio for today is 24.19.
The historical data trend for Corcept Therapeutics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics Annual Data | |||||||||||||||
Trend | 2018-12 | 2019-12 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | 2024-04 | ||||||||
Forward PE Ratio | 11.42 | 13.07 | 36.90 | 19.42 | 17.39 | 33.11 | 147.06 |
Corcept Therapeutics Quarterly Data | ||||||||||||||||||||||||
2018-06 | 2018-09 | 2018-12 | 2019-03 | 2019-06 | 2019-09 | 2019-12 | 2020-03 | 2020-06 | 2020-09 | 2020-12 | 2021-03 | 2021-06 | 2021-09 | 2021-12 | 2022-03 | 2022-06 | 2022-09 | 2022-12 | 2023-03 | 2023-06 | 2023-09 | 2023-12 | 2024-03 | |
Forward PE Ratio | 14.43 | 12.30 | 11.42 | 12.22 | 13.12 | 16.10 | 13.07 | 11.51 | 17.51 | 16.58 | 36.90 | 24.51 | 30.30 | 20.70 | 19.42 | 25.64 | 26.04 | 22.22 | 17.39 | 28.65 | 36.76 | 29.76 | 33.11 | 76.34 |
For the Biotechnology subindustry, Corcept Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Corcept Therapeutics (NAS:CORT) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Thank you for viewing the detailed overview of Corcept Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Swisher Daniel N Jr | director | C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
William Guyer | officer: Chief Development Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Gary Charles Robb | officer: CHIEF FINANCIAL OFFICER | C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Joseph Douglas Lyon | officer: Chief Accounting Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Sean Maduck | officer: See Remarks | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
David L Mahoney | director | SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014 |
Hazel Hunt | officer: Chief Scientific Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Joseph K Belanoff | director, officer: CHIEF EXECUTIVE OFFICER | 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Baker G Leonard Jr | director, 10 percent owner | 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005 |
Joshua M. Murray | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Atabak Mokari | officer: Chief Financial Officer | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Gillian Cannon | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Gregg H Alton | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Kimberly Park | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Andreas Grauer | officer: Chief Medical Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
From GuruFocus
By GuruFocus Research • 11-01-2023
By GuruFocus Research • 12-07-2023
By Value_Insider Value_Insider • 10-27-2022
By Value_Insider Value_Insider • 12-08-2022
By Business Wire Business Wire • 12-16-2022
By Marketwired • 07-26-2023
By Value_Insider Value_Insider • 11-03-2022
By PurpleRose PurpleRose • 07-27-2022
By sperokesalga sperokesalga • 05-03-2023
By Marketwired • 07-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.